Osimertinib Holds Its Own in NSCLC.
An updated, final analysis from the phase III FLAURA study showed that compared with older EGFR inhibitors, the third-generation drug osimertinib was better tolerated and significantly improved overall survival among patients newly diagnosed with EGFR-mutant non-small cell lung cancer.